Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic peptide-derived compound that has generated intense research interest due to its extraordinary potency in promoting synaptogenesis. Developed by Joseph Harding and colleagues at Washington State University, Dihexa operates through the hepatocyte growth factor (HGF)/c-Met receptor system and demonstrates cognitive-enhancing effects in preclinical models at picomolar concentrations—making it approximately seven orders of magnitude more potent than brain-derived neurotrophic factor at stimulating new synaptic connections.
Development from Angiotensin IV Research
Dihexa emerged from decades of research into the brain renin-angiotensin system. While the systemic renin-angiotensin system (RAS) primarily regulates blood pressure, a parallel brain RAS exists with distinct functions. Angiotensin IV (Ang IV), a metabolic fragment of angiotensin II, was found to enhance memory and learning in animal models through its receptor AT4 (subsequently identified as insulin-regulated aminopeptidase, IRAP).
Harding’s group developed stable Ang IV analogs and discovered that their cognitive effects were not mediated through IRAP as originally thought, but through potentiation of hepatocyte growth factor (HGF) signaling via the c-Met receptor. This mechanistic redirection led to the rational design of Dihexa—optimized for HGF/c-Met activation rather than IRAP binding.
HGF/c-Met Signaling in the Brain
Hepatocyte growth factor (HGF) is a pleiotropic growth factor with important roles in brain development and maintenance. In the adult brain, HGF/c-Met signaling promotes dendritic spine formation and maintenance, synaptic plasticity, neuronal survival against excitotoxic and oxidative stress, and hippocampal long-term potentiation (LTP). HGF/c-Met signaling declines with age and is reduced in Alzheimer’s disease and other neurodegenerative conditions.
Dihexa enhances HGF/c-Met signaling by stabilizing the HGF dimer in its active conformation. HGF exists as a two-chain disulfide-linked heterodimer, and the stability of this dimer influences the duration and intensity of c-Met receptor activation. Dihexa binds at the dimer interface, preventing dissociation and maintaining sustained c-Met phosphorylation and downstream signaling through PI3K/Akt and MAPK/ERK pathways.
Synaptogenesis and Cognitive Effects
In hippocampal neuron cultures, Dihexa dramatically increased the number of dendritic spines (the structural substrate of excitatory synapses) at concentrations as low as 10 picomolar. This synaptogenic effect was approximately 10 million-fold more potent than BDNF on a molar basis—an unprecedented potency for a cognitive-enhancing compound. The new spines exhibited mature mushroom-type morphology and contained synaptic markers (PSD-95, synaptophysin), indicating functional synapse formation.
In animal models, Dihexa improved performance on spatial memory tasks (Morris water maze, radial arm maze) in both young and aged rats. Aged rats treated with Dihexa performed comparably to young controls on hippocampal-dependent memory tasks. The cognitive enhancement was blocked by c-Met inhibitors, confirming the dependence on HGF/c-Met signaling.
In a scopolamine-induced amnesia model (which disrupts cholinergic signaling to impair memory), Dihexa fully reversed the cognitive deficit, suggesting its synaptogenic effects can compensate for cholinergic dysfunction. This finding has implications for dementia research where cholinergic deficits are a hallmark feature.
Alzheimer’s Disease Research
Dihexa has been specifically investigated in preclinical Alzheimer’s models. In transgenic mice expressing human amyloid precursor protein (APP), Dihexa treatment improved spatial memory and reduced amyloid plaque burden. The mechanism may involve HGF-mediated neuroprotection against amyloid-beta toxicity and enhanced synaptic connectivity to compensate for synapse loss—the strongest correlate of cognitive decline in Alzheimer’s disease.
Oral Bioavailability
A notable feature of Dihexa is its oral bioavailability, unusual for peptide-derived compounds. The modified structure (with hexanoic acid caps replacing standard amino acid termini) provides resistance to gastrointestinal and hepatic peptidases, allowing oral administration in research models. Brain penetration following oral dosing has been confirmed through pharmacokinetic studies, with effective brain concentrations achieved within hours.
Research Limitations
Despite its remarkable preclinical profile, several cautions apply. All data comes from cell culture and rodent models; no human clinical trials have been conducted. The long-term effects of sustained synaptogenesis are unknown—excessive synaptic connectivity could theoretically produce excitotoxicity or epileptiform activity. The HGF/c-Met pathway has oncogenic potential (c-Met is an established proto-oncogene), raising safety questions about chronic activation. These concerns require thorough investigation before clinical translation.
Frequently Asked Questions
What is Dihexa?
Dihexa is a synthetic peptide analog derived from angiotensin IV research. It potently activates HGF/c-Met signaling to promote synaptogenesis at picomolar concentrations, making it one of the most potent nootropic compounds identified.
How potent is Dihexa?
Approximately 10 million times more potent than BDNF at promoting new synapse formation in vitro. Active at picomolar concentrations.
What is the HGF/c-Met pathway?
HGF/c-Met signaling promotes dendritic branching, synaptogenesis, and neuronal survival. Dihexa potentiates this pathway by stabilizing the HGF dimer and enhancing c-Met receptor activation.